Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib

Alopecia areata is a non-scarring form of hair loss with an undetermined etiology that can profoundly affect patients both cosmetically and psychologically. As immune cells are implicated in the pathogenesis, molecularly targeted drugs can be used for therapy. This report presents a case of a patient who suffered from alopecia areata for two years. Our patient failed to respond to standard therapy using traditional Chinese medicine techniques. This necessitated a shift to a different drug with improved efficacy and outcomes. Initial treatment revealed that the patient had ritlecitinib-resistant alopecia areata, which showed significant signs of recovery following treatment with upadacitinib. By the 24-week follow-up, all symptoms of alopecia had sufficiently normalized. This report also highlights the advantages of upadacitinib and the role of JAK1-mediated pathways in certain patients with alopecia. Thus, It suggests that adoption of personalized treatment strategies might have an effect for patients with alopecia areata.